Hide metadata

dc.date.accessioned2024-02-05T17:47:44Z
dc.date.available2024-02-05T17:47:44Z
dc.date.created2023-11-20T12:54:23Z
dc.date.issued2023
dc.identifier.citationSpasevska, Ivana Sharma, Ankush Steen, Chloe Beate Josefsson, Sarah Elisabet Blaker, Yngvild Nuvin Kolstad, Arne Rustad, Even Holth Meyer, Saskia Isaksen, Kathrine Thuestad Chellappa, Stalin Kushekhar, Kushi Beiske, Klaus Hermann Førsund, Mette S Spetalen, Signe Holte, Harald Østenstad, Bjørn Brodtkorb, Marianne Kimby, Eva K Olweus, Johanna Tasken, Kjetil Newman, Aron M Lorenz, Susanne Smeland, Erlend Bremertun Alizadeh, Ash A. Huse, Kanutte Myklebust, June Helen . Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Advances. 2023, 7(23), 7216-7230
dc.identifier.urihttp://hdl.handle.net/10852/107532
dc.description.abstractAbstract Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest substantial heterogeneity in the phenotypes and suppressive capacities of Tregs, emphasizing the importance of understanding Treg diversity and the need for additional markers to identify highly suppressive Tregs. Here, we applied single-cell RNA sequencing and T-cell receptor sequencing combined with high-dimensional cytometry to decipher the heterogeneity of intratumoral Tregs in diffuse large B-cell lymphoma and follicular lymphoma (FL), compared with that in nonmalignant tonsillar tissue. We identified 3 distinct transcriptional states of Tregs: resting, activated, and unconventional LAG3+FOXP3− Tregs. Activated Tregs were enriched in B-NHL tumors, coexpressed several checkpoint receptors, and had stronger immunosuppressive activity compared with resting Tregs. In FL, activated Tregs were found in closer proximity to CD4+ and CD8+ T cells than other cell types. Furthermore, we used a computational approach to develop unique gene signature matrices, which were used to enumerate each Treg subset in cohorts with bulk gene expression data. In 2 independent FL cohorts, activated Tregs was the major subset, and high abundance was associated with adverse outcome. This study demonstrates that Tregs infiltrating B-NHL tumors are transcriptionally and functionally diverse. Highly immunosuppressive activated Tregs were enriched in tumor tissue but absent in the peripheral blood. Our data suggest that a deeper understanding of Treg heterogeneity in B-NHL could open new paths for rational drug design, facilitating selective targeting to improve antitumor immunity.
dc.languageEN
dc.publisherAmerican Society of Hematology
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleDiversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
dc.title.alternativeENEngelskEnglishDiversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
dc.typeJournal article
dc.creator.authorSpasevska, Ivana
dc.creator.authorSharma, Ankush
dc.creator.authorSteen, Chloe Beate
dc.creator.authorJosefsson, Sarah Elisabet
dc.creator.authorBlaker, Yngvild Nuvin
dc.creator.authorKolstad, Arne
dc.creator.authorRustad, Even Holth
dc.creator.authorMeyer, Saskia
dc.creator.authorIsaksen, Kathrine Thuestad
dc.creator.authorChellappa, Stalin
dc.creator.authorKushekhar, Kushi
dc.creator.authorBeiske, Klaus Hermann
dc.creator.authorFørsund, Mette S
dc.creator.authorSpetalen, Signe
dc.creator.authorHolte, Harald
dc.creator.authorØstenstad, Bjørn
dc.creator.authorBrodtkorb, Marianne
dc.creator.authorKimby, Eva K
dc.creator.authorOlweus, Johanna
dc.creator.authorTasken, Kjetil
dc.creator.authorNewman, Aron M
dc.creator.authorLorenz, Susanne
dc.creator.authorSmeland, Erlend Bremertun
dc.creator.authorAlizadeh, Ash A.
dc.creator.authorHuse, Kanutte
dc.creator.authorMyklebust, June Helen
cristin.unitcode185,53,18,75
cristin.unitnameK.G. Jebsen senter for B-cellekreft - del UiO
cristin.ispublishedfalse
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2198837
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Blood Advances&rft.volume=7&rft.spage=7216&rft.date=2023
dc.identifier.jtitleBlood Advances
dc.identifier.volume7
dc.identifier.issue23
dc.identifier.startpage7216
dc.identifier.endpage7230
dc.identifier.doihttps://doi.org/10.1182/bloodadvances.2023010158
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2473-9529
dc.type.versionPublishedVersion
dc.relation.projectNFR/332727
dc.relation.projectKF/515850
dc.relation.projectSKGJ/Grant 19, Jebsen Ctr. B cell malignancies
dc.relation.projectNFR/315538
dc.relation.projectNFR/294916
dc.relation.projectNFR/230817
dc.relation.projectKF/245270
dc.relation.projectKF/162948
dc.relation.projectKF/182694


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International